April 20, 2024

• 

[THE INVESTOR] Medytox, South Korea’s largest botulinum toxin product maker, seeks to unveil its new wrinkle-fighting product -- that makes patients less likely to develop resistance to the neurotoxin -- later this year here, the company said March 17.  

“We plan to launch the new product in the second half of the year following production capability expansion of our third plant which started operations in December,” an official at the firm told The Investor.

Its third plant, which the company expects to generate products worth 600 billion won (US$536.4 million) a year, started operations in December last year.

The product named Coretox, differentiates itself by being a purer product than other winkle fighters Botox, lacking complexing proteins, which could lead to a negative reaction causing a patient to discontinue injections or require a higher dose

According to the official, Medytox’s third toxin product also has enhanced safety profile by not using albumin and substance that comes from animals. In Korea, German pharmaceutical firm Merz launched similar product Xeomin, free from complexing proteins, which is increasing market share in the highly competitive cosmetic injectable market here.

Coretox received approval from the Korean Ministry of Food and Drug Safety in June last year.

Medytox has also developed the powder-type botulinum toxin Neuronox, approved by the US Food and Drug Administration, and liquid-injectable product Innotox.

By Park Han-na (hnpark@heraldcorp.com)